ST万邦(002082.SZ)子公司WP107药品多剂量爬坡临床研究获得FDA许可

智通财经07-16

智通财经APP讯，ST万邦(002082.SZ)发布公告，公司全资子公司万邦德制药集团有限公司自主研发用于全身型重症肌无力治疗的新药WP107(石杉碱甲口服溶液)，于近期获得美国食品药品监督管理局(简称“FDA”)批准本品用于健康试验参与者的多剂量爬坡临床试验研究。据悉，此次获得FDA许可的多剂量爬坡临床研究是一项安慰剂对照的单中心、随机、双盲、多次给药、剂量递增的药代动力学研究，旨在评估石杉碱甲...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2651244331?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-16 17:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651244331","market":"sh","top_or_hot":-1,"title":"ST万邦(002082.SZ)子公司WP107药品多剂量爬坡临床研究获得FDA许可","media":"智通财经","content":"<div>\n<p>智通财经APP讯，ST万邦(002082.SZ)发布公告，公司全资子公司万邦德制药集团有限公司自主研发用于全身型重症肌无力治疗的新药WP107(石杉碱甲口服溶液)，于近期获得美国食品药品监督管理局(简称“FDA”)批准本品用于健康试验参与者的多剂量爬坡临床试验研究。据悉，此次获得FDA许可的多剂量爬坡临床研究是一项安慰剂对照的单中心、随机、双盲、多次给药、剂量递增的药代动力学研究，旨在评估石杉碱甲...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1468510.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ST万邦(002082.SZ)子公司WP107药品多剂量爬坡临床研究获得FDA许可</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nST万邦(002082.SZ)子公司WP107药品多剂量爬坡临床研究获得FDA许可\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-16 17:59 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1468510.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，ST万邦(002082.SZ)发布公告，公司全资子公司万邦德制药集团有限公司自主研发用于全身型重症肌无力治疗的新药WP107(石杉碱甲口服溶液)，于近期获得美国食品药品监督管理局(简称“FDA”)批准本品用于健康试验参与者的多剂量爬坡临床试验研究。据悉，此次获得FDA许可的多剂量爬坡临床研究是一项安慰剂对照的单中心、随机、双盲、多次给药、剂量递增的药代动力学研究，旨在评估石杉碱甲...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1468510.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0028","symbol_name":"国家队","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1468510.html","article_id":"2651244331","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2651244331","pubTimestamp":1784195963,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，ST万邦 发布公告，公司全资子公司万邦德制药集团有限公司自主研发用于全身型重症肌无力治疗的新药WP107，于近期获得美国食品药品监督管理局批准本品用于健康试验参与者的多剂量爬坡临床试验研究。通过与FDA的沟通交流，该项目无需开展单剂量爬坡研究。同时，FDA也认可了中国多剂量爬坡研究数据对后续全球研发及重症肌无力患者研究的支持作用。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK0028":"国家队","BK0050":"建筑节能","BK0239":"医药制造","LABU":"三倍做多标普生物-Direxion","BK4588":"碎股","BK4585":"ETF&股票定投概念","002082":"ST万邦","BK0004":"股权转让"},"translate_title":"ST Wanbang (002082.SZ) subsidiary WP107 drug multi-dose climbing clinical study obtained FDA approval","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":1.5,"002082":1.5},"content_text":"智通财经APP讯，ST万邦(002082.SZ)发布公告，公司全资子公司万邦德制药集团有限公司自主研发用于全身型重症肌无力治疗的新药WP107(石杉碱甲口服溶液)，于近期获得美国食品药品监督管理局(简称“FDA”)批准本品用于健康试验参与者的多剂量爬坡临床试验研究。据悉，此次获得FDA许可的多剂量爬坡临床研究是一项安慰剂对照的单中心、随机、双盲、多次给药、剂量递增的药代动力学研究，旨在评估石杉碱甲口服溶液在健康试验参与者体内多次给药的安全性、耐受性及该制剂的药代动力学特征。通过与FDA的沟通交流，该项目无需开展单剂量爬坡研究。同时，FDA也认可了中国多剂量爬坡研究数据对后续全球研发及重症肌无力患者研究的支持作用。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2651244331","isCrawlerRequest":true}